Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year to date total to almost $4B(covered here, here). Four of the last five quarters are amongst the largest record-setting quarters in ten years.
It’s one of the best periods for biotech funding in the history of the industry, offering an opportunity for emerging companies to scale and develop their pipelines more significantly than ever before.